Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired …
S Pasca, C Ambaglio, A Rocino, C Santoro… - Journal of Thrombosis …, 2019 - Springer
Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
[PDF][PDF] Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired …
S Pasca, C Ambaglio, A Rocino, C Santoro, I Cantori… - 2018 - academia.edu
Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired …
S Pasca, C Ambaglio, A Rocino… - … of Thrombosis and …, 2019 - search.proquest.com
Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired …
S Pasca, C Ambaglio, A Rocino, C Santoro… - … OF THROMBOSIS AND …, 2019 - iris.unipa.it
Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
[PDF][PDF] Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired …
S Pasca, C Ambaglio, A Rocino, C Santoro, I Cantori… - 2018 - centroemofiliapadova.it
Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired …
S Pasca, C Ambaglio, A Rocino, C Santoro… - JOURNAL OF …, 2019 - boa.unimib.it
Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
[PDF][PDF] Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired …
S Pasca, C Ambaglio, A Rocino, C Santoro, I Cantori… - 2018 - researchgate.net
Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired …
S Pasca, C Ambaglio, A Rocino… - JOURNAL OF …, 2019 - research.unipd.it
Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired …
S Pasca, C Ambaglio, A Rocino… - … of thrombosis and …, 2019 - pubmed.ncbi.nlm.nih.gov
Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired …
S Pasca, C Ambaglio, A Rocino, C Santoro… - … of Thrombosis and …, 2019 - europepmc.org
Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …
hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and …